# Study of Cannabidiol in Sanfilippo Syndrome

> **NCT06333041** · PHASE2,PHASE3 · RECRUITING · sponsor: **Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center** · enrollment: 35 (estimated)

## Conditions studied

- Sanfilippo Syndrome
- Mucopolysaccharidosis III

## Interventions

- **DRUG:** Epidiolex
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06333041
- **Lead sponsor:** Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-04
- **Final completion:** 2028-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06333041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06333041, "Study of Cannabidiol in Sanfilippo Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06333041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*